Physician profile
Maria E Borelli
NPI 1689868960
$3,376.50
in general payments reported to CMS, 2019-2025
30 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $531 · 2021: $1,030 · 2022: $736 · 2023: $562 · 2024: $297 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,038.38 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $549.55 | 2020-2024 | Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $284.89 | 2020-2022 | |
| Astellas Pharma US INC | $130.45 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.09 | 2020-2023 | Jardiance |
| Glaxosmithkline, LLC. | $121.12 | 2021-2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $117.67 | 2020-2024 | Mounjaro, Trulicity, Zepbound |
| Biohaven Pharmaceuticals, INC. | $111.03 | 2021 | |
| Abbott Laboratories | $85.58 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.96 | 2022 | |
| Allergan, INC. | $64.70 | 2020 | |
| Pfizer INC. | $61.16 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.18 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $52.62 | 2020-2021 | |
| Amgen INC. | $44.78 | 2020-2023 | Evenity, Prolia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.52 | 2020-2022 | |
| Medtronic, INC. | $43.90 | 2023-2025 | Venaseal |
| Bausch Health US, LLC | $36.18 | 2021 | |
| Sumitomo Pharma America, INC. | $34.86 | 2025 | Gemtesa |
| Eisai INC. | $31.43 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $31.37 | 2021-2022 | |
| Axsome Therapeutics, INC. | $30.55 | 2024 | Auvelity |
| Esperion Therapeutics, INC. | $29.59 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $26.32 | 2022 | |
| Horizon Therapeutics Plc | $25.60 | 2020-2022 | |
| Myriad Women'S Health, INC. | $25.43 | 2023 | Myrisk |
| Jazz Pharmaceuticals INC. | $24.72 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.67 | 2020 | |
| Intuitive Surgical, INC. | $24.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Borelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.